Epalinges, Switzerland, October 16, 2018 – Mymetics Corporation (OTCQB:MYMX), a pioneer and leader in the research and development of virosome-based vaccines, announced today that Mymetics BV, the Dutch subsidiary of Mymetics Corporation, has entered into a research collaboration project with eTheRNA immunotherapy NV, a clinical stage biotech company developing novel mRNA cancer immunotherapies.
The objective of the project is to evaluate the suitability of Mymetics’ proprietary virosome vaccine delivery technology in combination with eTheRNA’s proprietary TriMix mRNA. eTheRNA will evaluate the duration and intensity of mRNA expression when formulated with virosome technology in vivo and the induction of antigen specific T cells and antitumor efficacy upon therapeutic vaccination in selected tumor models.
Mymetics’ virosome particles have shown to be able to trigger good specific T cell responses as virosomes are able to be absorbed and processed by dendritic cells, thereby presenting specific antigens to T cells to promote immunity against these foreign antigens.

Press release